APT Pharmaceuticals


APT Pharmaceuticals is focused on the development of cyclosporine inhalation solution (CIS) for the prevention and treatment of chronic rejection in lung transplantation. The company has successfully enrolled a large, multi-center Phase III clinical trial evaluating the effect of CIS on chronic rejection. APT is preparing for study data and commercialization of the product in the US and Europe. The company has an experienced management team and has partnered with leaders in the field of life sciences investing..


Date Type Amount Investors Valuation
10/05/07 Series A 22M Charter Life Sciences, Great Point Partners, RCT, Versant Ventures, Vivo Ventures Unknown
09/01/08 Series B 32.3M Three Arch Partners, InterWest Partners, Pinnacle Ventures Unknown


Sue Barrowcliffe (Vice-President, Regulatory)

Joe Melvin (Vice-President, Finance)

Stephen Dilly (President/CEO)

Paul Sekhri (President/CEO)

View more details about all 16 people at APT Pharmaceuticals